Skip to main content
ACXP logo

ACXP · Acurx Pharmaceuticals, Inc.

Track ACXP — free
$1.42 +0.02 (+1.43%) At close · Sep 4
Market Cap
$7.48M
Shares
5.27M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.42 Open$1.40 Day$1.39–1.42 52W close$1.35–8.10 Avg vol 30d163K Short int94K · 1.8% float · 1.0d Short vol25% Last earningsAug 14, 2026 DataAug 2025–Sep 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Aug 5, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 15, 2026 Est · unconfirmed · in 10 wks
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
Trailing 12 months
Net income (TTM)
−$7.51M
Trailing 12 months
Revenue growth YoY
Year over year
Operating margin
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
$10.66M
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+257.9%
Year over year · more shares
Price change (1Y)
-63.2%
Trailing year
Short interest
1.8%
Latest settlement · 1.0 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −41%
below
Price vs 50-day avg −4%
below
RSI (14) 47
neutral
MACD trend Negative
52-week position 1%
near low
Momentum
relative strength
Very Weak
1-month return −8%
trailing
6-month return −70%
trailing
YTD return −43%
this year
Relative strength −86%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.79% of float · ▼ -26.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
20 holders — mid 3-yr range
Squeeze score 36
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 186%
annualized · 1-yr
Max drawdown −83%
past year
ATR 6.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−41% Bearish
Price vs 50-day avg
−4% Neutral
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.79% of float · ▼ -26.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
20 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $8
vs 200-day avg -41% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACXP
Acurx Pharmaceuticals, Inc.
this stock
$7.48M -43.0% 1.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
$138.42B +20.5% +46.2% 31.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$85.22B +7.2% +20.8% 20.5 2.3%
ARGX
Argenx SE
$64.25B +22.9% 1.9%
CSLLY
Csl Ltd
$60.55B 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
20
% held
2.4%
Net QoQ
-58.8K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
94.1K
Days to cover
1.0d
Change
-33.8K sh
View
Short Volume
Short vol %
25%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
3.4K
Value
$4.9K
As of
Aug 3, 2026
View
Off-Exchange
Off-exchange %
64.6%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-8.0M
EPS diluted
$-5.32
View
Filings
SEC Filings
Latest
DEF 14A
Filed
Sep 1, 2026
This year
6
View
Exempt Offerings
Offering
$4.6M
Filed
Apr 29, 2026
View
Earnings & Events
Earnings Calls Upcoming
Next call
Oct 16, 2026
Last call
Aug 14, 2026
View
Investor Relations
Upcoming events
1
View

Performance

Raw-price comparisons begin at the captured split on Aug 5, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
ACXP -1.4% -7.8% -70.5% -2.1% -43.0%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -1.5% -7.4% -85.6% -2.5% -55.9%
Key facts CIK 1736243 CUSIP 00510M203 13F (30d) 14 filings 14 filers Visit website Investor relations